Literature DB >> 17683002

Baseline HIV type 1 coreceptor tropism predicts disease progression.

Eric S Daar1, Karen L Kesler, Christos J Petropoulos, Wei Huang, Michael Bates, Alice E Lail, Eoin P Coakley, Edward D Gomperts, Sharyne M Donfield.   

Abstract

BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) coreceptor tropism, the ability of the virus to enter cells via CCR5 or CXCR4, is a viral characteristic mediated by the envelope gene. The impact of coreceptor tropism on the natural history of HIV-1 infection has not been fully explored.
METHODS: Coreceptor tropism was measured using a recombinant virus single-cycle assay on plasma specimens obtained at baseline from 126 children and adolescents in the Hemophilia Growth and Development Study cohort who were enrolled from 1989 through 1990 and underwent follow-up through 1997.
RESULTS: Detectable CXCR4-using virus at baseline was associated with a lower baseline CD4(+) T cell count and a higher plasma HIV-1 RNA level. In addition, it independently predicted a greater decrease in CD4(+) T cell count over time (P<.001) and was associated with a 3.8-fold increased risk of progression to clinical AIDS.
CONCLUSIONS: This study demonstrates that coreceptor tropism, as assessed by this single-cycle assay, independently influences the natural history of HIV-1 disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17683002     DOI: 10.1086/520650

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  46 in total

1.  Pilot studies for development of an HIV subtype panel for surveillance of global diversity.

Authors:  Mark Manak; Silvana Sina; Bharathi Anekella; Indira Hewlett; Eric Sanders-Buell; Viswanath Ragupathy; Jerome Kim; Marion Vermeulen; Susan L Stramer; Ester Sabino; Piotr Grabarczyk; Nelson Michael; Sheila Peel; Patricia Garrett; Sodsai Tovanabutra; Michael P Busch; Marco Schito
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-24       Impact factor: 2.205

2.  Analysis of HIV tropism in Ugandan infants.

Authors:  Jessica D Church; Wei Huang; Anthony Mwatha; Philippa Musoke; J Brooks Jackson; Danstan Bagenda; Saad B Omer; Deborah Donnell; Clemensia Nakabiito; Chineta Eure; Laura A Guay; Allan Taylor; Paul M Bakaki; Flavia Matovu; Michelle McConnell; Mary Glenn Fowler; Susan H Eshleman
Journal:  Curr HIV Res       Date:  2010-10       Impact factor: 1.581

3.  Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.

Authors:  Wei Huang; Arne Frantzell; Jonathan Toma; Signe Fransen; Jeannette M Whitcomb; Eric Stawiski; Christos J Petropoulos
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.616

Review 4.  Novel targets for antiretroviral therapy: clinical progress to date.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Newer antiretroviral agents and how to use them.

Authors:  Holly H Kim; Eric S Daar
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

6.  Newer antiretroviral agents and how to use them.

Authors:  Holly H Kim; Eric S Daar
Journal:  Curr Infect Dis Rep       Date:  2009-07       Impact factor: 3.725

7.  Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals.

Authors:  Wei Huang; Jonathan Toma; Eric Stawiski; Signe Fransen; Terri Wrin; Neil Parkin; Jeannette M Whitcomb; Eoin Coakley; Frederick M Hecht; Steven G Deeks; Rajesh T Gandhi; Susan H Eshleman; Christos J Petropoulos
Journal:  AIDS Res Hum Retroviruses       Date:  2009-08       Impact factor: 2.205

8.  CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression.

Authors:  Lucy A McNamara; Adewunmi Onafuwa-Nuga; Nadia T Sebastian; James Riddell; Dale Bixby; Kathleen L Collins
Journal:  J Infect Dis       Date:  2013-04-03       Impact factor: 5.226

Review 9.  CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.

Authors:  Michelle B Kim; Kyle E Giesler; Yesim A Tahirovic; Valarie M Truax; Dennis C Liotta; Lawrence J Wilson
Journal:  Expert Opin Investig Drugs       Date:  2016-12       Impact factor: 6.206

10.  Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.

Authors:  Wei Huang; Jonathan Toma; Signe Fransen; Eric Stawiski; Jacqueline D Reeves; Jeannette M Whitcomb; Neil Parkin; Christos J Petropoulos
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.